Rare diseases, spotlighting amyotrophic lateral sclerosis, Huntington’s disease, and myasthenia gravis: Insights from landscape analysis of current research

Rumiana Tenchov,Kavita Iyer,Janet Sasso,Krittika Ralhan,Jyotsna Jotshi,Dmitrii Polshakov,Ankush Maind,Qiongqiong Angela Zhou

DOI: https://doi.org/10.26434/chemrxiv-2024-rkqvt-v2

2024-08-12

Abstract:Rare diseases are a diverse group of disorders that despite each individual condition's rarity, collectively affect a significant portion of the global population. Currently approximately 10,000 rare diseases exist globally, with 80% of these diseases being identified as having genetic origins. In this review, we examine data from the CAS Content CollectionTM to summarize scientific progress in the area of rare diseases. We examine the publication landscape in the area in effort to provide insights into current advances and developments. We then discuss the evolution of key concepts in the field, genetic associations, as well as the major technologies and development pipelines of rare disease treatments. We focus our attention on three specific rare diseases: (i) amyotrophic lateral sclerosis, a terminal neurodegenerative disease affecting the central nervous system resulting in progressive loss of motor neurons that control voluntary muscles; (ii) Huntington’s disease, another terminal neurodegenerative disease that causes progressive degeneration of nerve cells in the brain, with a wide impact on a person's functional abilities; and (iii) myasthenia gravis, a chronic autoimmune synaptopathy leading to skeletal muscle weakness. While the pathogenesis of these rare diseases is being elucidated, there is neither a cure nor preventative treatment available, only symptomatic treatment. The objective of the paper is to provide a broad overview of the evolving landscape of current knowledge on rare diseases, and specifically on the biology and genetics of the three spotlighted diseases, to outline challenges and evaluate growth opportunities, an aim to further efforts in solving the remaining challenges.

Chemistry

What problem does this paper attempt to address?

The problems that this paper attempts to solve are the knowledge gaps and challenges in the field of rare diseases, especially for three specific rare diseases: Amyotrophic Lateral Sclerosis (ALS), Huntington’s Disease (HD) and Myasthenia Gravis (MG). By analyzing the data in the CAS content collection, the paper aims to provide a review of the latest progress in the biology and genetics of these diseases, and to outline the evolution of key concepts, technological development and treatment development pipelines in the current research field. In addition, the paper also explores the challenges existing in rare disease research and evaluates the growth opportunities, in order to further promote the efforts to solve the unsolved problems in this field.

Specifically, the goals of the paper include:
1. **Provide a comprehensive review**: Conduct a comprehensive review of the current knowledge system of rare diseases, with special attention to the biological and genetic aspects of ALS, HD and MG.
2. **Outline the challenges**: Describe in detail the challenges faced in rare disease research and treatment, such as difficulties in diagnosis and limited treatment methods.
3. **Evaluate growth opportunities**: Evaluate the growth opportunities for future research and treatment development to promote further research and treatment of rare diseases.
4. **Raise awareness**: Through detailed data analysis and literature review, raise awareness of the importance of rare disease research.

Through these goals, the paper hopes to provide valuable resources and insights for the research and development of rare diseases and promote scientific research and clinical applications in this field.